British Journal of Pharmacology · 2007 · 76 citations · 35 references
MedicineImmunologyPharmacologyImmunopharmacologyInflammationInnate ImmunityAnti-inflammatory PharmacologyEicosanoid BiosynthesisInflammation PharmacologyLeukocyte Recruitment5-Lipoxygenase Activation5-Lipoxygenase InhibitionCyclooxygenase InhibitorsLipoxygenase Inhibition
BACKGROUND AND PURPOSE: Licofelone is a dual inhibitor of the cyclooxygenase and 5-lipoxygenase (5-LO) pathway, and has been developed for the treatment of inflammatory diseases. Here, we investigated the molecular mechanisms underlying the inhibition by licofelone of the formation of 5-LO products. EXPERIMENTAL APPROACH: The efficacy of licofelone to inhibit the formation of 5-LO products was analysed in human isolated polymorphonuclear leukocytes (PMNL) or transfected HeLa cells, as well as in cell-free assays using respective cell homogenates or purified recombinant 5-LO. Moreover, the effects of licofelone on the subcellular redistribution of 5-LO were studied. KEY RESULTS: Licofelone potently blocked synthesis of 5-LO products in Ca(2+)-ionophore-activated PMNL (IC(50)=1.7 microM) but was a weak inhibitor of 5-LO activity in cell-free assays (IC(50)>>10 microM). The structures of licofelone and MK-886, an inhibitor of the 5-LO-activating protein (FLAP), were superimposable. The potencies of both licofelone and MK-886 in ionophore-activated PMNL were impaired upon increasing the concentration of arachidonic acid, or under conditions where 5-LO product formation was evoked by genotoxic, oxidative or hyperosmotic stress. Furthermore, licofelone prevented nuclear redistribution of 5-LO in ionophore-activated PMNL, as had been observed for FLAP inhibitors. Finally, licofelone as well as MK-886 caused only moderate inhibition of the synthesis of 5-LO products in HeLa cells, unless FLAP was co-transfected. CONCLUSIONS AND IMPLICATIONS: Our data suggest that the potent inhibition of the biosynthesis of 5-LO products by licofelone requires an intact cellular environment and appears to be due to interference with FLAP.
35
The PyMOL Molecular Graphics System
Warren L. DeLano · Medical Entomology and Zoology · 2002 · 18.1K citations
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
Richard A. F. Dixon, Ronald E. Diehl, Evan E. Opas et al. · Nature · 1990 · 776 citations
Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene
Xin-Sheng Chen, James R. Shelter, Eric N. Johnson et al. · Nature · 1994 · 417 citations
John W. Gillard, A W Ford‐Hutchinson, Chi-Chung Chan et al. · Canadian Journal of Physiology and Pharmacology · 1989 · 328 citations
Medicine, Biochemistry, Pharmacology +14